Header

Esophageal Cancer Clinical Trials

Category:Adult
Status:Active

Displaying all 7 trials

Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer

The purpose of this study is to determine whether nivolumab will improve overall survival, disease-free survival, or both compared with placebo.

Diagnosis: Esophageal Cancer, Gastrointestinal Malignancies

Phase: 3

Protocol Number: 16-197

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

This research study is a Phase II clinical trial to test the safety and effectiveness of the investigational drug Ziv-aflibercept in combination with mFOLFOX6 compared to mFOLFOX6 alone. The drugs ...

Diagnosis: Gastrointestinal Malignancies, Esophageal Cancer, Stomach Cancer

Phase: 2

Protocol Number: 12-401

Safety and Efficacy of FGF401 in Patients With Solid Malignancies

Estimate the maximum tolerated dose and/or recommended phase two dose and efficacy of FGF401 on patients with solid malignancies

Diagnosis: Gastrointestinal Malignancies, Stomach Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer

Phase: 1 / 2

Protocol Number: 14-464

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal juncti...

Diagnosis: Esophageal Cancer, Gastrointestinal Malignancies

Phase: 1 / 2

Protocol Number: 16-258

Pembrolizumab in Refractory Advanced Esophageal Cancer

This research study is studying a targeted therapy as a possible treatment for advanced esophageal cancer. The study intervention involved in this study is: -Pembrolizumab

Diagnosis: Gastrointestinal Malignancies, Esophageal Cancer

Phase:

Protocol Number: 16-293

Physical Activity In Gastrointestinal Cancer

This research study is evaluating the ability for people with metastatic gastrointestinal cancer to participate in a physical activity program.

Diagnosis: Pancreatic Cancer, Colorectal Cancer, Gastrointestinal Malignancies, Esophageal Cancer

Phase:

Protocol Number: 17-350

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

This pilot phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junc...

Diagnosis: Esophageal Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 18-708

'